Myelomas
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (79635322MMY3002)
- Details
ClinicalTrials.gov ID:
NCT07518186
Diagnosis Type:
NA
USOR Number:
- Address
,
P: